Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer

NCT01537536 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: EndoTAG-1

Sponsor

Jules Bordet Institute